VIVO Cannabis Inc. provided an update on its medical cannabis business.
Medical cannabis patients with authorizations in Canada can now purchase a variety of Canna Farms™ craft premium dried flower and pre-roll strains and solventless concentrates through the Medical Cannabis by Shoppers™ online sales platform. Canna Farms™ Kief and Bubble Hash products are the first in their concentrate categories to launch with Medical Cannabis by Shoppers™ and offer experienced patients the option of higher potency, quicker onset of action delivery formats.
“We’re proud to offer our quality-tested products through a trusted pharmacy network which is helping to shape the medical cannabis community,” said Barry Fishman, Chief Executive Officer of VIVO. “We have aligned visions for product standardization and consistency for medical cannabis patients, and we look forward to further collaboration with Medical Cannabis by Shoppers Drug Mart Inc. and the introduction of additional novel products.”
VIVO also announced that a selection of its Canna Farms™ and Beacon Medical™ products will be available to patients in the previously announced University Health Networks’ (“UHN”) Medical Cannabis Real-World Evidence Study, in partnership with Medical Cannabis by Shoppers Drug Mart Inc.
Led by UHN’s Dr. Hance Clark, the first-of-its-kind, prospective, non-interventional, observational study that will involve a nation-wide clinical trial to examine the impact of medical cannabis on sleep, pain, anxiety and depression issues. The study will enroll about 2,000 patients who will be followed over a 24-week period to determine the efficacy of medical cannabis on producing positive health outcomes.
As part of the study, all Canna Farms™ and Beacon Medical™ products will undergo additional testing, with results registered on TruTrace Technologies software platform that is integrated through the Medical Cannabis by Shoppers online platform and will capture detailed data about each product for patients in the clinical trial. VIVO products starting in the new year.
“We are excited to participate in this groundbreaking study in partnership with UHN and Medical Cannabis by Shoppers Drug Mart Inc.,” said Carole Chan, Chief Commercial Officer of VIVO. “At VIVO, we are uniquely committed to our medical business and are supportive of this concerted effort to bring greater clarity and consistency to the medical cannabis space, by elevating the standards of quality control.”
VIVO Cannabis™ is recognized for trusted, premium cannabis products and services. It holds production and sales licences from Health Canada and operates world-class indoor and seasonal airhouse cultivation facilities. VIVO has a collection of premium brands, each targeting different customer segments, including Canna Farms™, Beacon Medical™, Fireside™, Fireside-X™, Lumina™ and Canadian Bud Collection™. Harvest Medicine, VIVO’s patient-centric, scalable network of medical cannabis clinics, has serviced over 150,000 patient visits. VIVO is pursuing several partnership and product development opportunities and is focusing its international efforts on Germany and Australia. For more information visit: vivocannabis.com
